GlassScriptPhysician profile
Joseph Catanzaro
NPI 1437197712
$1,847.56
in general payments reported to CMS, 2019-2025
29 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $92.16 · 2021: $155 · 2022: $308 · 2023: $271 · 2024: $432 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.83 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $320.83 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $211.07 | 2021-2025 | |
| Abbvie INC. | $201.70 | 2019-2025 | Skyrizi |
| Lilly USA, LLC | $140.14 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $128.24 | 2021-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $93.28 | 2020-2023 | |
| Incyte Corporation | $80.42 | 2021-2024 | Opzelura |
| Botanix Sb INC | $75.94 | 2025 | Sofdra |
| Celgene Corporation | $48.30 | 2019 | |
| Biofrontera INC. | $45.26 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.40 | 2019-2020 | |
| Pfizer INC. | $44.12 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $40.70 | 2022-2024 | Nuzyra |
| Almirall LLC | $39.96 | 2025 | Klisyri |
| Ucb, INC. | $38.61 | 2024 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $37.97 | 2025 | Ycanth |
| Genzyme Corporation | $35.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.35 | 2022-2023 | Sotyktu |
| Organon LLC | $27.12 | 2025 | |
| Organogenesis INC. | $26.70 | 2025 | Affinity |
| Misonix INC | $21.38 | 2020 | |
| Smith+Nephew, INC. | $20.05 | 2025 | Collagenase Santyl |
| Genentech USA, INC. | $19.82 | 2024 | Erivedge |
| Bioventus LLC | $18.06 | 2022 | |
| Allergan, INC. | $15.47 | 2019 | |
| Arcutis Biotherapeutics, INC. | $15.03 | 2023 | |
| Strata Skin Sciences, INC. | $12.37 | 2022 | |
| Novum Pharma, LLC | $11.38 | 2019 | |
| Prugen, INC. Pharmaceuticals | $6.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Catanzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.